Workflow
Pharmaceuticals and Medical Devices
icon
Search documents
Why CorMedix (CRMD) Might be Well Poised for a Surge
ZACKS· 2025-08-14 17:21
Core Viewpoint - CorMedix (CRMD) is experiencing solid improvement in earnings estimates, which is likely to positively impact its stock price momentum [1][2] Earnings Estimates - Analysts show growing optimism regarding CorMedix's earnings prospects, reflected in upward revisions of earnings estimates [2][3] - The consensus earnings estimate for the current quarter is $0.30 per share, indicating a year-over-year increase of +700.0% [6] - For the full year, the expected earnings are $1.22 per share, representing a year-over-year change of +506.7% [7] Estimate Revisions - Over the past 30 days, the Zacks Consensus Estimate for CorMedix has increased by 30.43%, with two estimates moving higher and no negative revisions [6] - The consensus estimate for the full year has increased by 26.74% during the same timeframe [8] Zacks Rank - CorMedix currently holds a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on earnings estimate revisions [9] - Stocks with Zacks Rank 1 and 2 have historically outperformed the S&P 500 [9] Stock Performance - CorMedix shares have increased by 8.5% over the past four weeks, suggesting positive investor sentiment driven by impressive estimate revisions [10]
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
ZACKS· 2025-05-09 17:20
Core Insights - CorMedix (CRMD) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum [1][2] - The rising trend in estimate revisions reflects growing analyst optimism regarding the company's earnings prospects, which is expected to positively impact its stock price [2][3] Current-Quarter Estimate Revisions - The earnings estimate for the current quarter is $0.15 per share, representing a +160% change from the previous year [5] - The Zacks Consensus Estimate for CorMedix has increased by 114.29% over the last 30 days, with two estimates moving higher and no negative revisions [5] Current-Year Estimate Revisions - For the full year, CorMedix is expected to earn $0.93 per share, indicating a +410% change from the prior year [6] - The consensus estimate has increased by 40.91% over the past month, with one estimate moving higher and one negative revision [6][7] Favorable Zacks Rank - CorMedix currently holds a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts in raising earnings estimates [8] - Stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500, suggesting a favorable investment opportunity [8] Bottom Line - CorMedix's stock has risen by 75.9% over the past four weeks due to strong estimate revisions, indicating potential for further upside [9]